IDO1+ Paneth cells promote immune escape of colorectal cancer


Tumors have evolved mechanisms to escape anti-tumor immunosurveillance. They limit humoral and cellular immune activities in the stroma and render tumors resistant to immunotherapy. Sensitizing tumor cells to immune attack is an important strategy to revert immunosuppression. However, the underlying mechanisms of immune escape are still poorly understood. Here we discover Indoleamine-2,3-dioxygenase-1 (IDO1)+ Paneth cells in the stem cell niche of intestinal crypts and tumors, which promoted immune escape of colorectal cancer (CRC). Ido1 expression in Paneth cells was strictly Stat1 dependent. Loss of IDO1+ Paneth cells in murine intestinal adenomas with tumor cell-specific Stat1 deletion had profound effects on the intratumoral immune cell composition. Patient samples and TCGA expression data suggested corresponding cells in human colorectal tumors. Thus, our data uncovered an immune escape mechanism of CRC and identify IDO1+ Paneth cells as a target for immunotherapy.


Colorectal cancer (CRC) is the third most common cancer worldwide and patients with metastases in distant organs have a 5-year survival rate below 13%1. Metastatic CRC is currently treated with several combinations of cytotoxic agents. They improved overall survival of patients, treated initially with fluoropyrimidine monotherapy, from 12 to 30 months2. However, chemotherapy reached its limits3, which fostered clinical trials for immunotherapies4. The importance of immunosurveillance in CRC is emphasized by the good prognostic value of CD3+, CD8+, and CD45RO+ T-cell infiltration (Immunoscore)5,6,7. Unfortunately, immunotherapy with checkpoint inhibitors showed clinical benefits only in mismatch-repair-deficient CRC with high neo-antigen load. Durable responses in CRC with different etiologies remained scarce, which is due to immune escape mechanisms8.

The transcription factor signal transducer and activator of transcription 1 (Stat1) is a key effector in tumor immunosurveillance mediated by natural killer (NK)- and T cells9,10. Consistently, Stat1 is part of the immunologic constant of rejection gene expression signature, which correlates with good prognosis of CRC7. In cancer cells, Stat1 inhibits proliferation and promotes apoptosis via induction of cyclin-dependent kinase inhibitors and pro-apoptotic proteins9. Stat1 also regulates the expression of tissue antigens and proteins of the antigen presentation machinery, which enhance the immunogenicity of tumors11. Therefore, it is generally considered that Stat1 expression and activation in immune cells and in cancer cells suppresses tumorigenesis. Type I and II interferon (IFN) are the major activators of canonical Stat1 signaling, which relies on Tyr701 phosphorylation (pY-STAT1) and mediates tumor suppressive effects of IFN12. However, the tumor cell-intrinsic role of Stat1 in CRC is not well defined.

Lgr5+ stem cells at the bottom of intestinal crypts have been identified as possible precursor cells for CRC13. However, non-stem cells can also acquire tumor-initiating capacity14 and Lgr5+ cancer stem cells are not essential for growth of primary tumors15. These cells are separated by Lysozyme+ Paneth cells in the small intestine, which provide essential niche factors for stem cell proliferation and self-renewal16. In the colon, Lysozyme deep crypt base secretory cells support Lgr5+ stem cells16 but colonic Paneth cells can appear through epithelial metaplasia17. Paneth cells have been identified in intestinal tumors of ApcMin mice18 and in sporadic CRC of humans, albeit at varying frequencies ranging from 0.2% to 39%19. However, intestinal tumors from familial adenomatous polyposis (FAP) patients with inherited Apc mutations harbored more than 90% of Paneth cells20. The role of Paneth cells is unclear but CRC developed predominantly in colonic mucosal tissue with Paneth cell metaplasia21 and the presence of Paneth cell-containing adenomas increased the risk for synchronous CRC19. Therefore, Paneth cells might promote CRC formation.

Here we identified a subset of Paneth cells that displayed Stat1-dependent expression of the immune checkpoint molecule IDO1. Loss of these cells in Stat1-deficient intestinal tumors of ApcMin mice resulted in reduced tumor load and increased infiltration of anti-tumor immune cells.


Epithelial Stat1 promotes formation of intestinal tumors

We used ApcMin mice22 with conditional deletion of Stat1 in intestinal epithelial cells (Stat1∆IEC ApcMin)23,24 to identify Stat1 functions in intestinal tumorigenesis. Deletion of Stat1 was confirmed by PCR (Supplementary Fig. 1a), quantitative PCR (qPCR) of purified intestinal epithelial cells (Supplementary Fig. 1b) and immunohistochemistry (IHC, Supplementary Fig. 1c). Lamina propria cells of Stat1∆IEC ApcMin mice displayed STAT1 expression, which demonstrated specific ablation in intestinal epithelial cells (Supplementary Fig. 1c). Goblet, enteroendocrine, Paneth, and proliferating cells in the intestinal crypts were present at normal numbers in Stat1∆IEC ApcMin mice (Supplementary Fig. 1d-h). These data show that epithelial cell-specific deletion of Stat1 does not affect intestinal cell differentiation and crypt proliferation of ApcMin mice.

Four-month-old Stat1flox/flox ApcMin and Stat1∆IEC ApcMin mice were used to investigate epithelial cell-intrinsic functions of Stat1 in intestinal tumorigenesis. Tumor formation was reduced in Stat1∆IEC ApcMin male and female mice (Fig. 1a–c). Angiogenesis (Supplementary Fig. 2a), tumor cell proliferation, and apoptosis (Supplementary Fig. 2b) were not affected but numbers of low-grade adenomas were increased (Fig. 1d). These data show that epithelial cell-intrinsic Stat1 promotes the formation and progression of intestinal tumors in ApcMin mice.

Fig. 1: Reduced intestinal tumor burden in Stat1∆IEC ApcMin mice.

ac Quantification of tumor load (a), number (b), and mean area (c) in Stat1flox/flox ApcMin (7♀, 9♂) and Stat1∆IEC ApcMin (6♀, 13♂) mice. d Grading of tumors in Stat1flox/flox ApcMin (115 tumors, 9 mice) and Stat1∆IEC ApcMin (68 tumors, 9 mice) mice. Low grade: p < 0.001; high grade: p < 0.001; carcinoma: p = 0.473. e IHC staining demonstrating STAT1+ tumor cells (arrowheads) in Stat1flox/flox ApcMin colon tumors. STAT1 expression was not detectable in tumor cells of Stat1∆IEC ApcMin tumors but was increased in the stroma (arrow). Scale bars indicate 50 µm. f, g Quantification of STAT1+ tumor (f) and stroma (g) cells (f: Stat1flox/flox ApcMin si 12 tumors, 4 mice; colon 13 tumors, 4 mice; Stat1∆IEC ApcMin si 12 tumors, 4 mice; colon 12 tumors, 4 mice; g: 24 tumors of 4 mice each). h Venn diagram showing an overlap between human IRDS genes, IRDS genes downregulated in Stat1∆IEC ApcMin colon tumors, and genes that positively correlated with Stat1 expression in human CRC TCGA data. i Heat map of downregulated IRDS genes in Stat1∆IEC ApcMin colon tumors. j qPCR for Ifi44, Isg15, and Ido1 mRNA expression in colon tumors of Stat1flox/flox ApcMin (5 mice) and Stat1∆IEC ApcMin (6 mice) mice (tumors from each mouse were pooled). k ELISA for kynurenine in supernatants of Stat1flox/flox ApcMin (si: 7 tumors, 5 mice; colon: 7 tumors, 6 mice) and Stat1∆IEC ApcMin tumors (si: 7 tumors, 7 mice; colon: 7 tumors, 5 mice). l Quantification of iNOS+ and Granzyme B+ stroma cells (Stat1flox/flox ApcMin iNOS: 12 tumors, 4 mice; GZMB < 0.5 mm2: 9 tumors, 2 mice; >0.5 mm2: 21 tumors, 4 mice; Stat1∆IEC ApcMin iNOS: 14 tumors, 4 mice; GZMB < 0.5 mm2: 23 tumors, 5 mice; >0.5 mm2: 13 tumors, 3 mice). m, n FACS analysis of immune cells of Stat1flox/flox ApcMin (pooled tumors of 5 mice in 4 experiments) and Stat1∆IEC ApcMin (pooled tumors of 4 mice in 4 experiments) colon tumors. si: small intestine. Bars represent mean ± SEM.

ApcMin mice develop tumors mainly in the small intestine but also in the colon25. Similarly, we found tumors in the small intestine and the colon and stained them for STAT1 by IHC. STAT1 was detected in tumor and stroma cells of Stat1flox/flox ApcMin mice. In contrast, STAT1 was not detectable in tumor cells of Stat1∆IEC ApcMin tumors demonstrating efficient conditional deletion (Fig. 1e–g). However, Stat1∆IEC ApcMin tumors displayed a significant upregulation of STAT1 in the tumor stroma (Fig. 1e, g). Numbers of STAT3- and activated pY-STAT3-positive cells were not changed in Stat1∆IEC ApcMin tumors (Supplementary Fig. 2c-e). These data show that tumor cell-intrinsic Stat1 suppresses upregulation of Stat1 in the stroma of ApcMin tumors.

Tumor cell-intrinsic Stat1 suppresses immune cell activation

We have recently shown that enhanced anti-tumor immune cell activity is reflected by increased stromal Stat1 expression in azoxymethane-dextran sodium sulfate (AOM-DSS)-induced colorectal tumors26. Therefore, we investigated immune cell activation in Stat1∆IEC ApcMin tumors. As human intestinal tumors develop mainly in the colon, we performed RNA sequencing (RNA-seq) experiments with murine colon tumors (Supplementary Data 1 and 2). The analyses showed reduced expression of several IFN-stimulated genes (ISGs) in Stat1∆IEC ApcMin tumors (Supplementary Data 1). In particular, 24 out of 49 orthologs of human genes of the IFN-related gene signature for DNA damage (IRDS)27 were downregulated in Stat1∆IEC ApcMin tumors (Fig. 1i–j and Supplementary Data 1). We analyzed The Cancer Genome Atlas (TCGA) data to evaluate whether these genes are also regulated by Stat1 in human CRC. A correlation analysis revealed 529 genes that are co-expressed with Stat1 in human CRC (Supplementary Table 1). Among them were 16 IRDS genes. A Venn diagram using (i) human IRDS genes27, (ii) orthologs of human IRDS genes, significantly downregulated in Stat1∆IEC ApcMin mouse tumors, and (iii) the 529 genes, identified to be co-expressed with Stat1 in the CRC TCGA dataset, revealed a substantial overlap. A signature of 13 genes was present in all three gene sets (Fig. 1h). Gene Ontology (GO) term-enrichment analyses of deregulated genes in Stat1∆IEC ApcMin tumors and genes that are co-expressed with Stat1 in human CRC showed a substantial overlap of GO terms and revealed mainly pathways implicated in immunological processes (Supplementary Data 3 and 4). These data suggest that Stat1 target genes and Stat1-dependent regulation of immunological processes are similar in human and murine CRC.

Among the most significantly downregulated modulators of immune responses in Stat1∆IEC ApcMin tumors was the enzyme Indoleamine-2,3-dioxygenase-1 (Ido1, Fig. 1j, Supplementary Fig. 3a, and Supplementary Data 1), which acts as an immune checkpoint28. Other immune checkpoints were not deregulated in Stat1∆IEC ApcMin tumors but expression of the T-cell activation marker CD28 was increased (Supplementary Fig. 3a). IDO1 converts tryptophan into the immune-suppressive metabolite kynurenine. Consistently, levels of kynurenine were reduced in supernatants of Stat1∆IEC ApcMin tumors (Fig. 1k). We analyzed expression of inducible nitric oxide synthase (iNOS) and the serine protease Granzyme B, because they are markers for activation of several immune cells such as macrophages, mature dendritic cells, cytotoxic T cells, or NK cells. IHC characterization of the stroma showed increased numbers of activated iNOS+ immune cells (Fig. 1l). Numbers of Granzyme B+ cells were not significantly changed in large tumors but accumulated in small adenomas of Stat1∆IEC ApcMin mice (Fig. 1l and Supplementary Fig. 3b). Fluorescence-activated cell sorting (FACS) analysis of T cells demonstrated increased numbers of CD3+, CD4+, and CD8+ immune cells (Fig. 1m). However, the relative percentage of Granzyme B+ cells among the CD8+ population was not changed (Fig. 1n and Supplementary Fig. 3c). As kynurenine promotes differentiation of regulatory T cells (Tregs)29, we analyzed CD4+ CD25+ FoxP3+ cell infiltration by FACS. Treg numbers were significantly reduced in Stat1∆IEC ApcMin tumors (Fig. 1n and Supplementary Fig. 3c). It has also been reported that kynurenine promotes β-catenin nuclear localization in intestinal cancer cells30,31 but IHC staining revealed unchanged nuclear β-catenin levels in Stat1∆IEC ApcMin tumor cells (Supplementary Fig. 3d). These data suggest that tumor cell-intrinsic Stat1 suppresses stroma immune cell activation in ApcMin tumors through Ido1.

Stat1 promotes Ido1 expression in neoplastic Paneth cells

We performed IHC and IF staining to assess downregulation of Ido1 in Stat1∆IEC ApcMin tumors at the cellular level. This analysis revealed specific IDO1+ tumor cells in Stat1flox/flox ApcMin tumors that were absent in Stat1∆IEC ApcMin tumors (Fig. 2a, b, i). It has been shown that commercially available IDO1 antibodies are unspecific and unable to detect IDO1 in western blottings32. To address this issue for IHC staining, we performed in-situ hybridization (ISH) experiments and verified loss of IDO1+ tumor cells at the RNA level (Fig. 2a). The IDO1+ tumor cells were arranged in an alternating pattern with IDO1 tumor cells in neoplastic adenoma sheets (Fig. 2a). A similar arrangement was described for transformed Lgr5+ stem cells and Lysozyme+ Paneth cells in adenoma sheets of ApcMin tumors, which resembles crypt organization of the small intestine18. This suggests that IDO1+ tumor cells are either related to stem cells or to Paneth cells. Co-expression of Lgr5 and Ido1 mRNA was barely detectable by ISH in Stat1flox/flox ApcMin tumor cells (Fig. 2a), indicating that IDO1+ cells are Paneth cells. However, the ISH signals for Lgr5 were weak and not clearly attributable to individual cells. Therefore, double immunofluorescence (IF) with Paneth cell markers was performed. These analyses revealed protein expression of Paneth cell markers Lysozyme and MMP7 in IDO1+ tumor cells (Fig. 2c, g, h). More than 80% of IDO1+ tumor cells expressed Paneth markers (Fig. 2e, k), indicating that Paneth cells are the major source for Ido1 expression in the neoplastic epithelium. Double-positive cells were absent in Stat1∆IEC ApcMin tumors (Fig. 2c, g) but the overall numbers of Lysozyme+ and MMP7+ Paneth cells were not reduced (Fig. 2d, j). Moreover, about 50% of Paneth cells expressed IDO1 in Stat1flox/flox ApcMin tumors (Fig. 2f, l). These data demonstrate that Stat1 is required for the formation of IDO1+ Paneth cells in ApcMin tumors. IDO1+ Paneth cells are potential immunosuppressors and their absence might account for immunological changes in Stat1∆IEC ApcMin tumors. This assumption is challenged by the low number of IDO1+ Paneth cells in Stat1flox/flox ApcMin tumors (Fig. 2b, i). However, we identified a much higher percentage of IDO1+ Paneth cells in small and early ApcMin adenomas with almost 30% in the colon (Fig. 2m, n). These data suggest that IDO1+ Paneth cells support immune escape during early stages of ApcMin-induced tumorigenesis.

Fig. 2: Intestinal tumors of Stat1∆IEC ApcMin mice lack IDO1+ Paneth cells.

a IHC staining for IDO1 (upper panel) and double ISH for Ido1 and Lgr5 mRNA (lower panel) in Stat1flox/flox ApcMin and Stat1∆IEC ApcMin colon tumors. IDO1+ cells are indicated by arrowheads. Scale bars indicate 20 µm. b Quantification of IDO1+ tumor cells in IHC-stained tumors of Stat1flox/flox ApcMin (si and colon: 13 tumors, 4 mice) and Stat1∆IEC ApcMin (si: 12 tumors, 5 mice; colon: 13 tumors, 4 mice) mice. c IF staining for IDO1 and Lysozyme (LYZ1) in Stat1flox/flox ApcMin and Stat1∆IEC ApcMin colon tumors. Single fluorescent channels and composites are shown. Positive or double-positive cells are indicated by arrowheads. Scale bars indicate 50 or 10 µm (high-magnification insets). d Quantification of LYZ1+ tumor cells of Stat1flox/flox ApcMin (si and colon: 12 tumors, 4 mice) and Stat1∆IEC ApcMin (si: 8 tumors, colon 12 tumors, 4 mice each) tumors. e, f Quantification of percentages of LYZ1+ IDO1+ tumor cells between IDO1+ (e) and LYZ1+ (f) tumor cells of Stat1flox/flox ApcMin tumors. g IF staining for IDO1 and MMP7 in Stat1flox/flox ApcMin and Stat1∆IEC ApcMin colon tumors. Single fluorescent channels and composites are shown. Positive or double-positive cells are indicated by arrowheads. Scale bars indicate 50 µm. h IF staining for IDO1, MMP7, and E-Cadherin in Stat1flox/flox ApcMin tumors of the small intestine and colon. Triple-positive cells are indicated by arrowheads. Scale bars indicate 50 µm. i, j Quantification of IDO1+ (i) and MMP7+ (j) tumor cells in IF-stained tumors of Stat1flox/flox ApcMin (si: 7 tumors, 3 mice; colon: 12 tumors, 3 mice) and Stat1∆IEC ApcMin (si: 9 tumors, 3 mice; colon: 11 tumors, 3 mice) mice. k, l Quantification of percentages of MMP7+ IDO1+ tumor cells between IDO1+ (k) and MMP7+ (l) tumor cells of Stat1flox/flox ApcMin tumors. m, n IHC staining (m) and quantification (n) of IDO1+ Paneth cells in early and advanced Stat1flox/flox ApcMin tumors (si and colon: 12 early adenomas, 5 mice each and 13 advanced tumors, 4 mice each). Scale bars indicate 50 µm. si: small intestine. n.d.: not detectable. Bars represent mean ± SEM.

Ido1 is an ISG in human and murine tumor cells33, indicating a role of canonical Stat1 signaling in the formation of IDO1+ Paneth cells. IHC staining for canonical STAT1 activation detected <3% pY-STAT1+ tumor cells in Stat1flox/flox ApcMin tumors (Supplementary Fig. 4a, b). The pY-STAT1+ tumor cells appeared as cell clusters (Supplementary Fig. 4a), which differed from the alternating arrangement of IDO1+ Paneth cells. pY-STAT1 was undetectable in tumor cells of Stat1∆IEC ApcMin tumors (Supplementary Fig. 4a, b) but appeared upregulated in the stroma (Supplementary Fig. 4a, c) similar to upregulation of total STAT1 (Fig. 1e, g). We blunted type I IFN signaling by conditional deletion of Ifnar134 in ApcMin tumor cells. Tumor formation was not affected in the intestine of Ifnar1∆IEC ApcMin mice (Supplementary Fig. 4d-f). Moreover, the number of IDO1+ Paneth cells was comparable in Ifnar1flox/flox ApcMin and Ifnar1∆IEC ApcMin intestinal tumors (Supplementary Fig. 4g). These data demonstrate that the formation of IDO1+ Paneth cells in tumors of ApcMin mice is independent of type I IFN signaling.

We next investigated whether human CRC contain IDO1+ Paneth cells. Biopsies of 149 human T3 and T4 CRC that had not yet metastasized (Supplementary Table 2) were IHC-stained for STAT1 and IDO1 to compare staining patterns with Stat1flox/flox ApcMin mouse tumors. STAT1+ and IDO1+ cancer cells were readily detectable in human CRC but unlike mouse tumors, IDO1+ cells did not show an alternating pattern with IDO1 cells (Fig. 3a). However, a TCGA-based correlation matrix of ISGs (IRDS genes) and marker genes for cell identities revealed a correlation between the expression of Stat1, Ido1, and Lysozyme. Lysozyme clustered with Ido1- and Stat1-regulated IRDS genes (Fig. 3b). Moreover, we stained 14 early adenomas (5 from FAP patients) for neoplastic Lysozyme+ IDO1+ Paneth cells. Lysozyme+ and Lysozyme+ IDO1+ Paneth cells were found in ten adenomas (four from FAP patients) and six adenomas (three from FAP patients), respectively. In particular, FAP adenomas showed a perinuclear signal for IDO1 in Paneth cells (Fig. 3c). The relative contribution of Paneth cells to Ido1 expression was assessed by IF staining of the six adenomas harboring IDO1+ Paneth cells. About 50% of IDO1+ tumor cells were Lysozyme-positive, demonstrating a significant contribution of Paneth cells to Ido1 expression in the neoplastic epithelium (Fig. 3d). In summary, these data suggest that IDO1+ Paneth cells are present in human CRC.

Fig. 3: Evidence for Ido1-expressing Paneth cells in human CRC and early adenomas.

a IHC staining for STAT1 and IDO1 on consecutive tissue microarray (TMA) sections of human CRC. A tubular structure with cancer cells showing co-expression of STAT1 and IDO1 is indicated by arrowheads in the lower images (scale bars 50 µm). b Correlation matrix of TCGA expression data for Stat1, Ido1, IRDS genes, and markers for Paneth, Goblet, enteroendocrine, and cancer stem cells in human CRC. c IF staining for Lysozyme (LYZ) and IDO1 of a human adenoma biopsy of a FAP patient. The perinuclear signal for IDO1 is indicated by an arrowhead in the right high-magnification image (scale bar 50 µm). d IF staining was used for quantification of IDO1+ non-Paneth (LYZ) and Paneth (LYZ+) cells in the neoplastic epithelium of human adenomas.

IDO1+ CRC cells promote immune escape

Subcutaneous implantation of C57BL/6-derived MC38 cells into immunocompetent host mice is an established method for evaluation of pre-clinical immunotherapy approaches35. We transplanted green fluorescence protein (GFP)-labeled MC38 CRC cells to test whether deletion of Ido1 in neoplastic cells mimics immunologic consequences of IDO1+ Paneth cell ablation in Stat1∆IEC ApcMin tumors. Two independent MC38ΔIdo1-GFP subclones (MC38ΔIdo1-GFP-2 and MC38ΔIdo1-GFP-6) with CRISPR/Cas9-mediated deletion of the Ido1 locus were generated. The presence of INDELs in MC38ΔIdo1-GFP cells was verified by sequence analysis. Both clones contained an additional G in exon 6 of Ido1, which is a common CRISPR/Cas9-mediated insertion, and resulted in a truncated IDO1 protein (MC38ΔIdo1-GFP-2 cells are shown in Supplementary Fig. 5a, b). Sequencing revealed also a bigger deletion of the genomic locus upstream of the sgRNA targeting site in MC38ΔIdo1-GFP-2 cells, which might destabilize the Ido1 mRNA. Commercial antibodies are not suitable to detect a specific IDO1 protein by western blotting32. However, IFNγ stimulation induced Ido1 mRNA expression in MC38wt-GFP cells but not in MC38ΔIdo1-GFP-2 or MC38ΔIdo1-GFP-6 cells (Fig. 4a and Supplementary Fig. 5c). MC38ΔIdo1-GFP cells displayed a reduced cumulative cell number (Supplementary Fig. 5d), indicating an in-vitro proliferation defect similar to human cells31. In vivo, MC38ΔIdo1-GFP cells formed smaller tumors than MC38wt-GFP cells in immunocompetent C57BL/6 hosts (Fig. 4b, c), which were strongly infiltrated with CD3+ T cells (MC38ΔIdo1-GFP-2 cells are shown in Fig. 3d, e). In contrast, growth of MC38ΔIdo1-GFP-2 cells was not affected in immunocompromised NOD scid gamma (NSG) hosts, which lack mature T cells, B cells, and NK cells (Fig. 4f, g). We performed transplantation experiments with mixtures of cells to evaluate protective effects acting in trans. MC38ΔIdo1-GFP-6 cells were additionally labeled with dsRed to discriminate them from Ido1-proficient MC38wt-GFP cells. A 1 : 1 mixture of MC38wt-GFP/MC38ΔIdo1-G/RFP-6 cells showed comparable growth to MC38wt-GFP cells in immunocompetent C57BL/6 hosts, indicating that MC38wt-GFP cells restored growth of MC38ΔIdo1-G/RFP-6 cells in trans (Fig. 4h). IHC staining detected dsRed-positive cells close to the expected percentage in mixed tumors (Fig. 4i, j). Moreover, the prominent CD3+ T-cell infiltration in MC38ΔIdo1-GFP tumors (Fig. 4d, e) was abolished in mixed tumors (Fig. 4k). IHC staining revealed strong infiltration of Granzyme B+ immune cells in MC38ΔIdo1-G/RFP-6 tumors, which was also abolished in mixed tumors (Fig. 4l). These data demonstrate that Ido1+ MC38 CRC cells are able to promote immune escape of transplanted tumors.

Fig. 4: Ablation of Ido1 in MC38 cells interferes with tumor formation in immunocompetent host mice.

a qPCR for Ido1 mRNA expression in MC38wt-GFP and MC38ΔIdo1-GFP-2 cells 0, 1, and 24 h after IFNγ stimulation (n = 3). b, c Tumor size (b) and final tumor weight (c) after subcutaneous injection of MC38wt-GFP, MC38ΔIdo1-GFP-2, and MC38ΔIdo1-GFP-6 cells into C57BL/6 hosts (MC38wt-GFP: 7 tumors, 7 host mice; MC38ΔIdo1-GFP-2: 7 tumors, 4 host mice; MC38ΔIdo1-GFP-6: 7 tumors, 7 host mice). d, e IHC staining (d) and quantification (e) of CD3+ infiltrating cells in tumors of MC38wt-GFP (7 tumors) and MC38ΔIdo1-GFP-2 (6 tumors) cells. f, g Tumor size (f) and final tumor weight (g) of MC38wt-GFP and MC38ΔIdo1-GFP-2 tumors in NSG hosts (MC38wt-GFP: 15 tumors, 15 host mice; MC38ΔIdo1-GFP-2: 8 tumors, 8 host mice). h Tumor weight of MC38wt-GFP (15 tumors, 15 host mice), MC38ΔIdo1-G/RFP-6 (8 tumors, 8 host mice), and 1 : 1 mixed tumors (7 tumors, 7 host mice) in C57BL/6 hosts. i, j IHC staining (i) and quantitation (j) of GFP+ and dsRed(RFP)+ tumor cells in mixed tumors (n = 3). Expected percentages of positive cells are indicated by dashed lines. Scale bars indicate 100 µm. k, l Quantification of CD3+ (k) and Granzyme B+ (l) immune cells in MC38GFP-wt (three tumors each), MC38ΔIdo1-G/RFP-6 (four tumors each), and mixed tumors (three tumors each). n.d.: not detectable. Bars represent mean ± SEM.

Tumor cell-intrinsic Stat1-Ido1 favors progression of CRC

We investigated correlations of STAT1 and IDO1 protein expression in IHC-stained biopsies of 149 human T3 and T4 CRC (Supplementary Table 2). A score of 0–4 was attributed to STAT1 and IDO1 levels in tumor and stroma compartments (Supplementary Fig. 6). STAT1 or IDO1 protein in tumor or stroma cells did not correlate with overall survival and metastasis-free survival of patients (Supplementary Table 2). However, a strong correlation was observed between protein expression of STAT1 and IDO1 in tumor cells (Fig. 5a) and stroma cells (Fig. 5b). Additional analysis of TCGA data was used to increase the sample size. A correlation plot, derived from TCGA data, confirmed strong co-expression (Spearman score of 0.797) at the RNA level (Fig. 5c). Patient survival curves for Stat1 and Ido1 were similar (Fig. 5d, e), which is consistent with the co-expression of both genes. Patients with Stat1high or Ido1high cancers showed a trend towards improved survival 50 months after diagnosis (Fig. 5d, e), which might reflect beneficial effects of Stat1 in stromal immune cell activation. Consistently, immune metagene signature analysis36 revealed strong infiltration of anti-tumor immune cells in Stat1high tumors (Supplementary Fig. 7a). However, they also showed increased numbers of Tregs (Supplementary Fig. 7b), which could be due to tumor cell-intrinsic Stat1-Ido1 expression. Therefore, we looked for a surrogate marker to discriminate between tumor cell-intrinsic effects of Stat1-Ido1 expression and superimposing stromal effects. We have recently identified IFN-induced Protein with Tetratricopeptide 1 (Ifit1) as a surrogate marker for Stat1 expression in breast cancer cells, whereas stroma cells were Ifit1-negative37. We tested whether Ifit1 can also be employed as a specific surrogate marker for Stat1-Ido1 expression in the neoplastic epithelium of CRC. IHC staining of human biopsies demonstrated IFIT1 expression in CRC cancer cells but not in the tumor stroma (Supplementary Fig. 7c). Importantly, IFIT1 expression correlated strongly with STAT1 and IDO1 expression in CRC cancer cells (Supplementary Fig. 7c). Scoring of IDO1 and IFIT1 staining intensities (Supplementary Fig. 7d) confirmed a strong correlation of protein expression (Supplementary Fig. 7e, Pearson coefficient = 0.541). We first evaluated the prognostic value of stromal Stat1 expression in Ifit1low tumors. Ifit1low Stat1low and Ifit1low Stat1high tumors should display low Stat1-Ido1 expression in the neoplastic epithelium and low or high Stat1 expression in stroma cells, respectively. The Ifit1-based stratification significantly improved the prognostic value of Stat1 expression in CRC (p = 0.03, Fig. 5f). Patients with Ifit1low CRC benefited from high stromal Stat1 expression immediately after diagnosis, indicating that low expression of tumor cell-intrinsic Stat1-Ido1 sensitizes tumors to immune attack. We next mimicked conditions of our mouse models and stratified TCGA data into Ifit1high Stat1low and Ifit1low Stat1high CRC. Ifit1high Stat1low CRC (tumor cell-intrinsic Stat1-Ido1↑, stromal Stat1↓, similar to Stat1flox/flox ApcMin tumors) displayed a higher percentage of late-stage IV tumors than Ifit1low Stat1high CRC (tumor cell-intrinsic Stat1-Ido1↓, stromal Stat1↑, similar to Stat1∆IEC ApcMin tumors) (Fig. 5g, h), suggesting that tumor cell-intrinsic Stat1-Ido1 promotes CRC progression. Moreover, we employed the DeMixT algorithm38 to deconvolute tumor cell-intrinsic and stromal expression of Ido1 in TCGA data. We further stratified tumors into CMS1-4 consensus molecular subtypes39 and reinvestigated immune cell marker expression. Similarly, immune cell markers were predominantly expressed in the stroma. Moreover, the strongest expression was detected in the stroma of CMS1, a subtype characterized by immune cell infiltration39, as exemplified for T-cell markers (Supplementary Fig. 8a, b). Without tumor stroma deconvolution, patients with Ido1high tumors showed a slight trend towards better prognosis (Fig. 5d, p = 0.55). After deconvolution, survival curves for stroma and tumor compartments were laterally reversed (Supplementary Fig. 8c). Patients with strong Ido1 expression in the neoplastic epithelial cells showed a strong trend (p = 0.074) towards bad prognosis. Taken together, these data suggest that tumor cell-intrinsic Stat1-Ido1 expression favors immune escape and progression of human CRC.

Fig. 5: Use of Ifit1 as surrogate marker reveals a negative prognostic value of Stat1-Ido1 expression in the neoplastic epithelium of CRC.

a, b One hundred and forty-nine IHC-stained sections of human CRC were used to assess the correlation between STAT1 and IDO1 protein expression in the tumor cell compartment (a) and the stroma (b). c Scatter plot of TCGA expression data showing a strong correlation between Stat1 and Ido1 mRNA expression in human CRC. df Patient survival curves for Stat1high/low (d), Ido1high/low (e), and Ifitlow Stat1high/low (f) CRC using TCGA data. The median expression was used for stratification. g, h Stratification of human CRC into Ifit1low Stat1high and Ifit1high Stat1low cancer subtypes, and correlation with the tumor stage using TCGA data.

IDO1+ Paneth cells are present in normal crypts

Similar to tumors, Ido1 mRNA expression was downregulated in small intestinal and colonic IEC preparations of Stat1∆IEC ApcMin mice (Fig. 6a). Therefore, we wondered whether IDO1+ Paneth cells are present in normal crpyts. IHC and ISH analyses revealed IDO1+ vesicle-bearing Paneth cells in a subset of crypts of Stat1flox/flox ApcMin mice (Fig. 6b), which were abolished in Stat1∆IEC ApcMin crypts (Fig. 6b, c). We detected up to three IDO1+ cells in crypts of the small intestine and up to seven cells in colonic crypts (Fig. 6e). IDO1+ Paneth cells were also identified in Stat1flox/flox mice (Fig. 6c), demonstrating that their formation does not depend on the ApcMin allele. They were more abundant in the distal small intestine, which has a higher bacterial load, than in the proximal small intestine (Fig. 6c). Moreover, their abundance was decreased in mice that were housed in an extra clean special pathogen-free (SPF) facility and treated with antibiotics (Fig. 6c). Treated mice also displayed reduced numbers of Lysozyme+ Paneth cells in the proximal small intestine (Fig. 6d). These data suggest that the formation of IDO1+ Paneth cells is induced by the bacterial microbiome.

Fig. 6: IDO1+ Paneth cells are present in intestinal crypts and reduced in Ifngr1−/− mice.

a qPCR for Ido1 mRNA expression in isolated intestinal epithelial cells of Stat1flox/flox ApcMin (si: n = 4; colon: n = 5) and Stat1∆IEC ApcMin (si: n = 6; colon: n = 5) mice. b IHC staining for IDO1 (upper images) and double ISH for Ido1 and Lgr5 (lower images) in the small intestine of Stat1flox/flox ApcMin and Stat1∆IEC ApcMin mice. IDO1+ Paneth cells are indicated by arrowheads. Scale bars indicate 20 µm. ce Quantification of IDO1+ crypts (c), LYZ1+ Paneth cells/crypt (d), and IDO1+ cells/crypt (e) in different intestinal compartments of co-housed Stat1flox/flox ApcMin (n = 4), Stat1∆IEC ApcMin (n = 5), Stat1flox/flox (n = 4), Stat1∆IEC (n = 4), as well as C57BL/6 mice kept at an extra clean SPF facility with and without ABx treatment (n = 3 each). f qPCR for Ido1 mRNA expression after IFNγ stimulation in intestinal organoids of Stat1flox/flox (three technical replicates, two mice) and Stat1∆IEC (three technical replicates, three mice) mice. g IF showing the induction of IDO1 upon IFNγ stimulation in tumor organoids of Stat1flox/flox ApcMin mice. Scale bars indicate 50 µm. hj Quantification of IDO1+ crypts (h), LYZ1+ Paneth cells/crypt (i), and IDO1+ cells/crypt (j) in different intestinal compartments of co-housed C57BL/6 (n = 3) and Ifngr1−/− mice (n = 3). n.d.: not detectable; si: small intestine; SPF: special pathogen free; ABx: antibiotics. Bars represent mean ±  SEM.

It was previously shown that the TLR9 agonist ISS DNA can induce Ido1 in intestinal epithelial cells, which protects from colitis40. Therefore, we isolated intestinal organoids and stimulated them with immunostimulatory (ISS) DNA (ODN 1668). Lysozyme staining showed that Paneth cells were present in organoids but ISS DNA failed to induce Ido1 (Supplementary Fig. 8d, e). However, bacteria also promote IFNγ production by CD4+ T cells in the intestinal lamina propria41. IFNγ readily induced Ido1 in all epithelial cells of organoids at the RNA and protein level (Fig. 6f, g and Supplementary Fig. 8e). To further investigate the role IFNγ in vivo, we performed IHC for IDO1 in intestines of Ifngr1−/− mice42, which lack functional IFNγ signaling. The number of IDO1+ crypt cells was reduced in different intestinal parts of Ifngr1−/− mice (Fig. 6h, j). Interestingly, Ifngr1−/− mice displayed reduced numbers of Lysozyme+ Paneth cells in the proximal small intestine (Fig. 6i) similar to mice with antibiotic treatment (Fig. 6d). These data demonstrate a contribution of IFNγ in induction of IDO1+ Paneth cells.

Our data suggest that a bacteria/IFNγ axis is responsible for Ido1 induction in Paneth cells. Therefore, we analyzed single-cell RNA-seq (scRNA-seq) data of Haber et al.43 to investigate the impact of bacterial infection on Ido1 induction in Paneth cells. Paneth cell clusters were identified in t-distributed stochastic neighbor embedding (t-SNE) maps using marker genes (Supplementary Fig. 9a, b). Only two Ido1+ cells were found in t-SNE maps of healthy mice. Interestingly, they were both allocated to the Paneth-1 cell cluster, which is located in the distal small intestine and expresses the marker GM2100243. Haber et al.43 derived also scRNA-seq data from bacteria- and helminth-infected mice. Analysis of these data revealed a prominent induction of Ido1 in Paneth cells of bacteria- but not helminth-infected mice (Fig. 7a, b, d, f). Stat1 was induced in both infection models but more prominently by bacteria (Fig. 7a–c, e). These data demonstrate that the formation of Ido1+ Paneth cells is induced by the bacterial microbiome.

Fig. 7: Expression of Ido1 and Stat1 is induced in Paneth cells following bacterial infection.

ad t-SNE maps obtained from single-cell RNA-seq (full-length sequencing) of 389 epithelial cells from the small intestine of 7–10-week-old C57BL/6J mice without infection (control) and with infection (Heligmosomoides polygyrus or Salmonella enterica). Three paneth cell-enriched areas, which show increased expression of Ido1 following infection with Salmonella enterica are highlighted (red circles). e, f Violin plots for the expression of Stat1 and Ido1 (transcripts per million) in Paneth cells with and without infection. Single-cell RNA-seq data were generated by Haber et al.43 (GEO database: GSE92332). g Model how IDO1+ Paneth cells promote immune escape of CRC (for details, see discussion). CTL: cytotoxic T lymphocyte; Treg: regulatory T cell.


We identified an immune escape mechanism of CRC that is based on Stat1-dependent expression of Ido1 in Paneth cells. Paneth cell markers have previously been linked with intestinal tumorigenesis but the significance of the observations remained unclear. The markers Pla2g2a and Mmp7 were identified as modifiers of Min44 and loss of Mmp7, which is essential for Paneth cell function45, interfered with ApcMin-induced tumor formation46. Moreover, expression of Paneth markers correlated with increased risk for dietary-induced sporadic intestinal cancer in mice47 and a Paneth cell-associated gene expression pattern was identified in human intestinal tumors48. The presence of IDO1+ Paneth cells in intestinal cancers might provide an explanation for these observations. IDO1 increases local kynurenine levels and depletes tryptophan. Effector T cells respond to tryptophan depletion with cell cycle arrest49 and kynurenine promotes Treg differentiation via the aryl hydrocarbon receptor AhR29. This promotes an immune-tolerant microenvironment with reduced CD8+ T-cell activities and expansion of Tregs50,51,52. Ido1 overexpression is commonly observed in human CRC and associated with reduced serum tryptophan levels, whereas kynurenine metabolites are increased53,54,55. Localization studies have shown that Ido1 is expressed by infiltrating myeloid cells and neoplastic epithelial cells56,57,58, and both cellular compartments could contribute to kynurenine production. Our results suggest that the neoplastic epithelium is an important source for kynurenine, because loss of IDO1+ Paneth cells in Stat1∆IEC ApcMin tumors resulted in significantly reduced kynurenine levels that were not compensated by stromal kynurenine production. We speculate that neoplastic cells are major producers of kynurenine in tumors, whereas stromal myeloid cells use different metabolic routes. A contribution of Ido1-expressing neoplastic epithelial cells to immune escape has also been found in pancreatic ductal adenocarcinomas59 and high Ido1 expression in neoplastic epithelial cells at the invasive front is an independent adverse prognostic factor for overall survival and metastasis in CRC58,60,61.

Stat1 is considered as a tumor suppressor in solid cancers9 and we expected tumors of increased size in Stat1∆IEC ApcMin mice. However, tumors were smaller and contained reduced numbers of Tregs and increased numbers of CD8+ T cells. Similar neoplastic and immunologic aberrations were observed in Ido1−/− ApcMin tumors62. This indicates that loss of IDO1+ Paneth cells and corresponding immunological consequences surpassed tumor-promoting effects of Stat1 deletion in Stat1∆IEC ApcMin tumors. Interestingly, tumor formation was not affected in Stat1−/− ApcMin mice63 but this study neglected compensating effects of stromal Stat1 deletion, which interferes with immunosurveillance and alleviates the need for immunosuppression.

Most patients develop sporadic CRC, whereas colitis-associated CRC (CAC) affects only 1–2% of human cases. Recent studies demonstrated that specific deletion of Ido1 in intestinal epithelial cells interfered with AOM-DSS-induced CAC formation in mice30. The oncogenic function of Ido1 in CAC was attributed to tumor cell-intrinsic phosphatidylinositol-3-kinase–Akt-mediated nuclear translocation of β-catenin rather than immunosuppression30. Our results showed that Stat1 ablation and corresponding loss of IDO1+ tumor cells did not affect nuclear β-catenin levels in sporadic ApcMin tumors. This suggests that Ido1 promotes the formation of sporadic CRC and CAC through different mechanisms. Moreover, the neoplastic and immunological consequences of epithelial Stat1 deletion in CAC are different from sporadic CRC. We found increased AOM-DSS-induced CAC formation in male Stat1∆IEC mice64. Stat1∆IEC tumors contained reduced numbers of CD8+ T cells64, although IDO1+ Paneth cells were absent (unpublished data). Therefore, Stat1-dependent IDO1+ Paneth cells might be particularly important for the development of sporadic tumors but dispensable for CAC.

It is challenging to deduce prognostic information of tumor cell-intrinsic Stat1 and Ido1 expression from CRC TCGA data, because both genes are expressed in neoplastic cells and immune cells. Correspondingly, good prognosis of CRC patients with Stat1high tumors might be primarily caused by enhanced anti-tumor activity of Stat1high immune cells7, whereas prognostic information of Stat1 expression in neoplastic cells is masked. Using IHC staining of human samples, we identified IFIT1 as a surrogate marker for STAT1-IDO1 expression in cancer cells of human CRC. IFIT1 was not detectable in stromal cells and regulates the replication of viruses, a function that should not impact on human CRC prognosis. Ifit1 surrogate expression enabled us to discriminate between tumor cell-intrinsic and stromal Stat1-Ido1 functions in bulk gene expression TCGA data. These analyses suggested that tumor cell-intrinsic Stat1-Ido1 expression promotes progression of human CRC, correlates positively with Treg numbers and desensitizes tumors to immune attack. Moreover, Stat1-Ido1 expression correlated with Lysozyme expression in human TCGA data and IDO1+ Paneth cells were present in adenomas of FAP patients, indicating that human CRC also contain neoplastic IDO1+ Paneth cells.

Stat1-dependent IDO1+ Paneth cells were also found in normal murine crypts. They did not depend on ApcMin but the presence of the Min mutation affected their spatial distribution in the distal small intestine and colon. Extra clean SPF conditions and treatment of mice with antibiotics substantially reduced the number of IDO1+ crypts in all parts of the intestine. Moreover, IDO1+ Paneth cells in normal crypts were enriched in the distal small intestine, which has a high bacterial load, and we could identify Ido1 induction in Paneth cells of bacteria-infected mice using scRNA-seq data. This suggests that IDO1+ Paneth cells are induced by the local microbiome. TLR9 and IFN signaling are candidate pathways that could promote Ido1 expression in Paneth cells. The tumor studies with Ifnar1ΔIEC mice and ISS DNA-treated organoids suggest that Ido1 is not induced by type I IFN or TLR9 signaling. In contrast, IFNγ readily induced Ido1 in epithelial cells of organoids and IDO1+ Paneth cells were reduced in the intestine of Ifngr1−/− mice. However, in contrast to Stat1ΔIEC mice, IDO1+ Paneth cells were not completely abolished in Ifngr1−/− mice, indicating that additional factors are implicated in Stat1-Ido1 induction. Ido1 is an IFNγ-inducible gene in human and murine tumor cell lines33. The microbiome induces IFNγ production by mucosal T cells in mice41 and in humans65, and depletion of bacteria reduces IFNγ levels41. This indicates that interaction of lamina propria cells with the microbiome leads to the production of type II IFN that induces Stat1-dependent Ido1 expression in Paneth cells of distinct intestinal crypts.

In summary, we identified Stat1-dependent IDO1+ Paneth cells in intestinal tumors and normal intestinal crypts. They might represent bone fide Paneth cells but need Stat1 for Ido1 expression. IDO1+ Paneth cells could act as local immunosuppressors to prevent aberrant immune cell activation in response to bacteria. Hence, they could also provide immune-privileged niches for tumor formation (Fig. 7g). Early adenomas might use these niches to shield anti-tumor immune attack during elimination and equilibrium phases of immunoediting. Consistent with this idea, neoplastic IDO1+ Paneth cells were particularly abundant in early adenomas of ApcMin mice. Of note, tumor formation was impaired in ApcMin mice kept under germ-free conditions66. Targeting IDO1+ Paneth cells might improve efficacy of immunotherapy in microsatellite-stable CRC patients. Besides representing a conceptual advance, our findings will improve precision oncology of CRC.



Mice with floxed alleles of Stat124 or Ifnar134 were crossed to Villin-cre mice23. Villin-cre Stat1flox/flox and Villin-cre Ifnar1flox/flox animals were crossed with ApcMin mice22 (Jackson Laboratory) to generate Villin-cre Stat1flox/flox ApcMin/+ (Stat1∆IEC ApcMin) and Villin-cre Ifnar1flox/flox ApcMin/+ (Ifnar1∆IEC ApcMin) mice. Mice were kept on a C57BL/6 genetic background and housed under standard conditions at the Dezentrale Biomedizinische Einrichtung of the Medical University Vienna (Stat1∆IEC ApcMin) and the Zentrale Versuchstieranlage of the Medical University Innsbruck (Ifnar1∆IEC ApcMin). Experiments were performed with adult (6–8 weeks old) or tumor-bearing (4 months old) male or female mice. To deplete commensal gut microbiota, adult wild-type C57BL/6J mice were given ampicillin (1 g/l), vancomycin (0.5 g/l), neomycin sulfate (1 g/l), and metronidazole (1 g/l) in drinking water for 28 days. Water was changed every third day to ensure antibiotic stability. All mouse experiments were performed in accordance with Austrian and European laws (license numbers BMWFW-66.009/0191-WF/V/3b/2015 and BMWFW-66.009/0189-WF/V/3b/2015) and with the general regulations specified by the Good Science Practices guidelines of the Medical Universities Vienna and Innsbruck.

Human material

Patient material from the Austrian Breast and Colorectal Cancer Study 91 (ABCSG trial 91, NCT00309543) was used, which is a prospective, multicenter, randomized trial comparing the efficacy of adjuvant chemotherapy in stage II colon cancer67. All patients provided written consent and the study was approved by the ethics committees at the participating institutions.

Isolation of intestinal epithelial cells

Intestinal epithelial cells were isolated from 10–12-week-old mice as described previously68.

Histology, immunohistochemistry, and immunofluorescence

Intestines were flushed with phosphate-buffered saline (PBS) and 4% paraformaldehyde, fixed and embedded in paraffin as swiss rolls. Swiss rolls were cut into 2 µm sections and IHC/IF-stained with standard procedures using antibodies against β-catenin (Becton Dickinson, 610153, 1 : 80), BrdU (BrdU In-Situ Detection Kit, Becton Dickinson, 550803), cleaved Caspase 3 (Cell Signaling, 9661, 1 : 200), Endomucin (eBioscience, 14-5851-82, 1 : 500), GR1 (Serotec, MCA771GA, 1 : 200), Granzyme B (Abcam, ab4059, 1 : 200), IDO1 (Biolegend, 122402, 1 : 80), iNOS (Biolegend, 610431, 1 : 200), Ki67 (Novocastra, NCL-KI67-P, 1 : 1000), Lysozyme (Dako, A009902, 1 : 100), p-STAT1 (Cell Signaling, 9167S, 1 : 100), p-STAT3 (Cell Signaling, 9145, 1 : 100), STAT1 (Santa Cruz, sc-592, 1 : 500), STAT3 (Santa Cruz, sc-7179, 1 : 80), Synaptophysin (GeneTex, GTX100865, 1 : 1000), GFP (Roche, 11814460001, 1 : 1000), red fluorescent protein (RFP) (Rockland antibodies and assays, 600-401-379S, 1 : 500), CD3 (Neomarker RM9107, 1 : 100), MMP7 (Cell Signaling, 3801, 1 : 100). IHC staining on human samples was performed using antibodies against IFIT1 (Sigma Aldrich, HPA055380, 1 : 500), IDO1 (Biolegend, 122402, 1 : 100), p-STAT1 (Cell Signaling, 9167S, 1 : 100), and STAT1 (Cell Signaling, 14994, 1 : 1000).

CRISPR/Cas9 of MC38 cells and transplantation

MC38∆Ido1-GFP cells were generated using CRISPR-Cas9 as described previously69. Ido1 exon 6 was targeted using the following oligos: 5′-CACCTCCTGGTGGGGACTGCGACA-3′ (forward) and 5′-AAACTGTCGCAGTCCCCACCAGGA-3′ (reverse). Frequency of insertions/deletions in the transfected cell pool was estimated using the TIDE analysis software. The following primers were used for target site amplification: 5′-AACTCAGGGCTTTGAGAATGT-3′ and 5′-TTCATCCACTAAGCCACCCC-3′. Single cells derived from the initially targeted cell pool were expanded independently, sequenced for DNA modifications using the above mentioned primers, and used for transplantation experiments. To label MC38∆Ido1-GFP cells with dsRed, 10 µg of DsRed-pLenti plasmid (gift from Venugopal Bhaskara), 8 µg of packaging vector (psPAX2, Addgene plasmid # 12260), 3 µg of envelope vector (pVSV-G, Addgene plasmid # 14888), and 61 µl of 2 M CaCl2 were diluted to 500 µl in ddH2O. The solution was then mixed with 500 µl of 2× HBS (50 mM HEPES, 10 mM KCl, 12 mM Dextrose, 280 mM NaCl, 1.5 mM Na2HPO4 pH 7.05) and incubated for 10 min at room temperature, before being added to HEK293T cells for virus production. Target cells were incubated with virus containing supernatant for 5 days. Cells 106 were injected subcutaneously into the flanks of 8–9-week-old male C57BL/6J mice or NSG mice. To account for host effects, cells of different genotypes were implanted in the left and right flanks of the same mouse. Mixed MC38wt-GFP/MC38∆Ido1-G/RFP tumors were evaluated for the presence of GFP- and RFP-positive cells via IHC. Individual MC38wt-GFP and MC38∆Ido1-G/RFP tumors with 100% GFP+ or GFP+/dsRed+ cells were used for normalization of data.

MC38 cell stimulation

MC38wt-GFP and MC38∆Ido1-GFP cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum (FCS), 1% Penicillin/Streptomycin (10,000 U/ml) and 1% l-glutamine (200 mM). At 70–80% confluency, cells were stimulated with 100 ng/µl IFNγ (Immunotools, 12343536) for 1 h and 24 h, in triplicates.

Quantification and grading of Apc Min tumors

Swiss rolls were stained with hematoxylin and eosin, scanned with a Pannoramic Midi Slide Scanner (3D Histec), and histomorphometrically analyzed with DefiniensTM Developer software (Definiens). Grading was performed by a board certified pathologist (L.K.).

Flow cytometry

Intestinal tumors from single mice were pooled, minced and digested in 2 ml PBS containing 0.25% (v/v) FCS and 0.25% (w/v) collagenase IV (Life technologies, 17104-019) for 45’ at 37 °C under shaking. After straining through a 70 µm mesh and washing twice with 30 ml PBS, cells were incubated with TruStain fcX (Biolegend, 101320) and Zombie Aqua Fixable Viability Kit (Biolegend, 423102). Extracellular staining was performed using antibodies against CD8a (Biolegend, 100728), CD45 (Biolegend, 103128), CD4 (Biolegend, 100408), CD3e (eBioscience, 35-0031-82), and CD25 (eBioscience, 25-0251-81). Cells were fixed (Fixation/Permeabilization Buffer, eBioscience, 00-5123-43), permeabilized (Permeabilization Buffer, eBioscience, 00-8333-56), and intracellular staining of FOXP3 (Biolegend, 320011) and Granzyme B (Biolegend, 515405) was performed. Data were collected using a FACS Fortessa (BD) and analyzed with FlowJo software.

Enzyme-linked immunosorbent assay

Single tumors of the small intestine and colon were homogenized in 60 µl PBS and centrifuged. Supernatants were used for kynurenine ELISA (EMELCA Bioscience, MBS043489) according to the manufacturer’s instructions. The results were normalized for the amount of protein.

In-situ hybridization

Duplex ISH was performed on formalin-fixed paraffin-embedded tissue samples using RNAscope 2.5 HD assay (ACD, 322436) with probes against Lgr5 (ACD, 312171) and Ido1 (ACD, 315971) according to the manufacturer’s instructions.

RNA sequencing

Total RNA from tumors was extracted using TRIzol Reagent (Thermo Fisher Scientific, 15596018) and processed for sequencing using the TruSeq RNA Sample Preparation Kit (Illumina, Inc.) according to the manufacturer’s protocol. mRNA was purified using poly(T)-oligo-attached magnetic beads, fragmented, and applied to first-strand complementary DNA (cDNA) synthesis. Second-strand cDNA synthesis was performed using DNA polymerase I and RNase H. cDNA was end-repaired, A-tailed, ligated to adapters, and amplified to create the final cDNA library for sequencing (HiSeq2000, Illumina, Inc). TopHat2 algorithm was used to align raw RNA-seq data to mm10. Aligned bam files were deposited in ArrayExpress database (E-MTAB-5083). Differentially expressed genes were identified using DeSeq2 algorithm. An adjusted p < 0.005 and a fold change >2 or < −2 were defined as cut-off for differentially expressed genes. GO enrichment analyses were performed using GOrilla software.

scRNA-seq analysis

Pre-processed droplet-based scRNA-seq datasets from Haber et al.43 (GEO; GSE92332) were re-analyzed using the R package Seurat. For comparison of Ido1 expression in Paneth cell clusters, the infection model datasets “SH_Salmonella” and “SH_Hpoly” were used, as well as the according control sets. Different infection durations (3 days and 10 days) within the “SH_Hpoly” dataset were pooled. Furthermore, sequencing data of intestinal cells, specifically sorted with focus on large cells to improve Paneth cell yield, were analyzed. Dimensionality reduction was performed using gene expression data for a subset of variable genes. The variable genes were selected based on dispersion of binned variance to mean expression ratios using FindVariableGenes function of Seurat70 followed by filtering of ribosomal protein and mitochondrial genes. Next, principal component analysis (PCA) was performed and the data were reduced to the top 15 PCA (infection model)/10 PCA (large cells) components (number of components was chosen based on SDs of the principal components—in a plateau region of an elbow plot). Graph-based clustering of the PCA reduced data with the Louvain Method was used after computing a shared nearest-neighbor graph70. The clusters were visualized on a two-dimensional map produced with t-SNE. The VlnPlot function was applied to show expression probability distributions across the clusters and the FeaturePlot function to visualize feature expression within the clusters on a t-SNE plot. These methods were performed for marker genes of our cells of interest to identify Paneth and goblet cell clusters. Violin plot expression levels are depicted on a log transcripts per million (TPM) scale per cluster. Feature plot depicts a color scale for average gene expression. To identify further clusters containing Ido1+ cells (TA/Stem, Tuft, enterocytes), the top 50 specific marker genes for each cluster identified and described in Haber et al.43 were selected using the CaseMatch function and aggregated and matched to gene expression profiles of the clusters identified within this analysis using the MetaFeature function (calculation of relative contribution of each feature to each cell for given set of features).

Polymerase chain reaction

Wild-type, floxed and deleted Stat1 alleles were amplified using 5′-TAGGCTCCCTCTTTCCCTTC-3′, 5′-ACACCATTGGCTTCACCTTC-3′, and 5′-CCCCTGTCATCTGGAGTGAT-3′ primers. The Cre transgene was detected with 5′-CGGTCGATGCAACGAGTGATGAGG-3′ and 5′-CCAGAGACGGAAATCCATCGCTCG-3′ primers. ApcMin genotyping was performed using 5′-TCTCGTTCTGAGAAAGACAGAAGCT-3′ and 5′-TGATACTTCTTCCAAAGCTTTGGCTAT-3′ primers, and digestion of amplicons with HindIII.

Quantitative PCR

RNA was isolated with TRIzol (Life Technologies, 15596-018) and reverse transcribed with QuantiTect Reverse Transcription Kit (Qiagen, 205313). qPCR was performed using Fast SYBR Green Mastermix (Thermo Fisher Scientific, 4385616) and Applied Biosystems 7500 Fast Real Time PCR System with primers 5′-TGGTGAAATTGCAAGAGCTG-3′ and 5′-TGTGTGCGTACCCAAGATGT-3′ for Stat1, 5′-ATGTGGGCTTTGCTCTACCA-3′ and 5′-AAGCTGCCCGTTCTCAATCA-3′ for Ido1, and 5′-TGTTTGTGATGGGTGTG-3′ and 5′-TACTTGGCAGGTTTCTC-3′ for Gapdh.

Statistics and reproducibility

Sample sizes and numbers of replicates are described in detail in the figure legends. Biological replicates were defined as parallel measurements of biologically distinct samples (mice in most cases). Each experiment was repeated at least three times. All values are given as means ± SEM. Normal distribution of data was tested and appropriate tests were performed: comparisons of two groups were calculated with unpaired Student’s t-test or Mann–Whitney U-test. For more than two groups, one-way analysis of variance and Bonferroni’s post-hoc test or Kruskal–Wallis test, and Dunn’s post-hoc test were used. For analysis of the tumor and TMA gradings, χ2-test was used. Survival analyses using clinical data from CRC TCGA patients were performed using log-rank testing and GraphPad Prism 6 software. Correlation analyses of TCGA data were calculated using cor function of R3.2.1 software and visualization was performed using corrplot and ggplot2 packages. No sample size estimation was performed. Samples were excluded as outliers according to Grubbs’ test (α = 0.05). Experiments were performed and analyzed in a blinded, randomized manner. Significant differences between experimental groups are stated as: *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

RNA sequencing data were deposited in ArrayExpress database, accession number E-MTAB-5083. Previously generated single-cell RNA sequencing data analyzed here can be found in GEO (GSE92332). Processed (MapSplice aligned, RSEM quantified and upper-quartile normalization standardized; Level 3 RnaSeqV2) RNA sequencing data of the COADREAD dataset were obtained from The Cancer Genome Atlas (TCGA) database. All other data that support the findings of this study are available from the corresponding author upon reasonable request.


  1. 1.

    Siegel, R., Desantis, C. & Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 64, 104–117 (2014).

    PubMed  Article  Google Scholar 

  2. 2.

    Fakih, M. G. Metastatic colorectal cancer: current state and future directions. J. Clin. Oncol. 33, 1809–1824 (2015).

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Singh, P. P., Sharma, P. K., Krishnan, G. & Lockhart, A. C. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol. Rep. 3, 289–297 (2015).

    Article  Google Scholar 

  4. 4.

    Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361–375 (2019).

    PubMed  Article  Google Scholar 

  5. 5.

    Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Galon, J., Angell, H. K., Bedognetti, D. & Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26 (2013).

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Ciardiello, D. et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat. Rev. 76, 22–32 (2019).

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Meissl, K., Macho-Maschler, S., Muller, M. & Strobl, B. The good and the bad faces of STAT1 in solid tumours. Cytokine 89, 12–20 (2017).

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Leibowitz, M. S., Andrade Filho, P. A., Ferrone, S. & Ferris, R. L. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol. Immunother. 60, 525–535 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Strobl, B., Stoiber, D., Sexl, V. & Mueller, M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. (Landmark Ed.) 16, 3214–3232 (2011).

    Article  Google Scholar 

  13. 13.

    Ong, B. A., Vega, K. J. & Houchen, C. W. Intestinal stem cells and the colorectal cancer microenvironment. World J. Gastroenterol. 20, 1898–1909 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  14. 14.

    Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25–38 (2013).

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    de Sousa e Melo, F. et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 543, 676–680 (2017).

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Clevers, H. C. & Bevins, C. L. Paneth cells: maestros of the small intestinal crypts. Annu. Rev. Physiol. 75, 289–311 (2013).

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Zeuner, A., Todaro, M., Stassi, G. & De Maria, R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell 15, 692–705 (2014).

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730–735 (2012).

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Pai, R. K. et al. Paneth cells in colonic adenomas: association with male sex and adenoma burden. Am. J. Surg. Pathol. 37, 98–103 (2013).

    PubMed  Article  Google Scholar 

  20. 20.

    Porter, E. M., Bevins, C. L., Ghosh, D. & Ganz, T. The multifaceted Paneth cell. Cell Mol. Life Sci. 59, 156–170 (2002).

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Wada, R., Yamaguchi, T. & Tadokoro, K. Colonic Paneth cell metaplasia is pre-neoplastic condition of colonic cancer or not? J. Carcinogenesis 4, 5 (2005).

    Article  CAS  Google Scholar 

  22. 22.

    Su, L. K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668–670 (1992).

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193 (2004).

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Wallner, B. et al. Generation of mice with a conditional Stat1 null allele. Transgenic Res. 21, 217–224 (2012).

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Yamada, Y. & Mori, H. Multistep carcinogenesis of the colon in Apc(Min/+) mouse. Cancer Sci. 98, 6–10 (2007).

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Pathria, P. et al. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology 4, e998529 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  27. 27.

    Khodarev, N. N. et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl Acad. Sci. USA 101, 1714–1719 (2004).

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Sheridan, C. IDO inhibitors move center stage in immuno-oncology. Nat. Biotechnol. 33, 321–322 (2015).

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Bishnupuri, K. S. et al. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis. Cancer Res. 79, 1138–1150 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Thaker, A. I. et al. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 145(416-425), e411–e414 (2013).

    Google Scholar 

  32. 32.

    Van de Velde, L. A., Gingras, S., Pelletier, S. & Murray, P. J. Issues with the Specificity of Immunological Reagents for Murine IDO1. Cell Metab. 23, 389–390 (2016).

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    van Baren, N. & Van den Eynde, B. J. Tryptophan-degrading enzymes in tumoral immune resistance. Front. Immunol. 6, 34 (2015).

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Tschurtschenthaler, M. et al. Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut 63, 1921–1931 (2014).

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Xiao, Q. et al. DKK2 imparts tumor immunity evasion through beta-catenin-independent suppression of cytotoxic immune-cell activation. Nat. Med. 24, 262–270 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  37. 37.

    Tymoszuk, P. et al. High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer 14, 257 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  38. 38.

    Wang, Z. et al. Transcriptome deconvolution of heterogeneous tumor samples with immune infiltration. iScience 9, 451–460 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Ciorba, M. A. et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J. Immunol. 184, 3907–3916 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Hill, D. A. et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol. 3, 148–158 (2010).

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Huang, S. et al. Immune response in mice that lack the interferon-gamma receptor. Science 259, 1742–1745 (1993).

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Haber, A. L. et al. A single-cell survey of the small intestinal epithelium. Nature 551, 333–339 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Kwong, L. N. & Dove, W. F. APC and its modifiers in colon cancer. Adv. Exp. Med. Biol. 656, 85–106 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Ayabe, T. et al. Activation of Paneth cell alpha-defensins in mouse small intestine. J. Biol. Chem. 277, 5219–5228 (2002).

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L. & Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA 94, 1402–1407 (1997).

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Wang, D. et al. Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer. Proc. Natl Acad. Sci. USA 108, 10272–10277 (2011).

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Chen, X., Ehrhardt, W. M., Halberg, R. B., Aronow, B. J. & Dove, W. F. Cellular expression patterns of genes upregulated in murine and human colonic neoplasms. J. Histochem. Cytochem. 56, 433–441 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363–1372 (1999).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Holmgaard, R. B. et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13, 412–424 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Prendergast, G. C. et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother. 63, 721–735 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Zhai, L. et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin. Cancer Res. 21, 5427–5433 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Engin, A. B., Karahalil, B., Karakaya, A. E. & Engin, A. Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer. World J. Gastroenterol. 21, 3636–3643 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Liu, X. et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115, 3520–3530 (2010).

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Walczak, K. et al. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand. J. Gastroenterol. 46, 903–912 (2011).

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Theate, I. et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol. Res. 3, 161–172 (2015).

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Ferdinande, L. et al. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br. J. Cancer 106, 141–147 (2012).

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Blair, A. B. et al. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J. Clin. Invest. 129, 1742–1755 (2019).

    PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Brandacher, G. et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12, 1144–1151 (2006).

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Gao, Y. F. et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J. Transl. Med. 7, 71 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  62. 62.

    Takamatsu, M. et al. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice. Cancer Sci. 106, 1008–1015 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Liddle, F. J. & Frank, D. A. STAT1 expression is not required for polyp formation in Min mice. Mol. Carcinog. 47, 75–79 (2008).

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Crncec, I. et al. STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer. Mol. Oncol. 12, 514–528 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Li, Y. et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33, 1231–1238 (2012).

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Schippinger, W. et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br. J. Cancer 97, 1021–1027 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. 68.

    Zeineldin, M. et al. A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt signal inhibition and tumor suppression. Oncogene 31, 2423–2437 (2012).

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495–502 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


We thank Latifa Bakiri and Erwin F. Wagner for their critical reading of the manuscript. We thank Nina Braun for support with single-cell RNA-seq analysis. This work was supported by the Austrian Science Fund (FWF) Doktoratskolleg-plus grant “Inflammation and Immunity” (R.E., M.S., M.M., and B.S.), the FWF grants P29222-B28 (R.E.), F4709-B20 (G.H.), P26011 (L.K.), P32900 (E.C.), SFB F6101 (M.M. and B.S.), SFB F6106 (M.M. and B.S.), and the European Training Network MSCA-ITN-2015-ETN ALKATRAS No 675712 (L.K.).

Author information




Conceptualization, S.P., J. Svinka, and R.E. Methodology: S.P., J. Svinka, G.T., and E.G. Investigation: S.P., J. Svinka, I.S., I.C., M.F., P.C., L.K., M.A., M.S., R.B., D.H-B., Z.T., and G.H. Writing—original draft: R.E. Writing—review and editing: S.P., J. Svinka, I.C., E.G., M.S., Z.T., G.H., and R.E. Funding acquisition: L.K., G.H., M.S., M.M., B.S., and R.E. Resources: M.F., M.T., J. Stift, H.M., E.C., M.S., M.G., S.L., J.T., M.M., B.S., T.M., and A.K. Supervision: R.E.

Corresponding author

Correspondence to Robert Eferl.

Ethics declarations

Competing interests

The authors declare no competing interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pflügler, S., Svinka, J., Scharf, I. et al. IDO1+ Paneth cells promote immune escape of colorectal cancer. Commun Biol 3, 252 (2020).

Download citation


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.